Tapewire

Nasdaq · USD

INCY

INCYTE CORP

Export transactions ↓
Tapewire entity
3182
SEC CIK
0000879169
Parsed reports
950

Last 12 months

Inside the activity.

0 purchase rows · 46 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202507
Dec 202509
Jan 202602
Feb 202601
Mar 202601
Apr 202601
May 202602
Jun 202601
Jul 2026015
Aug 202605
Sep 202602
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
November 08, 2018 Filed Nov 9, 2018 21:21 UTC PurchaseCommon Stock 500 $68.91 $34,455.00
Disclosure

SEC source: 0001209191-18-057953 · doc4.xml · nonDerivative · entry 2

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,668

Read SEC document
November 08, 2018 Filed Nov 9, 2018 21:21 UTC PurchaseCommon Stock 500 $68.62 $34,310.00
Disclosure

SEC source: 0001209191-18-057953 · doc4.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,168

Read SEC document
October 03, 2018 Filed Oct 5, 2018 20:30 UTC
Trower PaulPrincipal Accounting Officer
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 10,000 $0.00 Strike: $17.79 $0.00
Disclosure

SEC source: 0001209191-18-054389 · doc4.xml · derivative · entry 3

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,187

Underlying: Common Stock · 10,000 shares

Expires 2019-01-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning January 19, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years

Read SEC document
October 03, 2018 Filed Oct 5, 2018 20:30 UTC
Trower PaulPrincipal Accounting Officer
SaleCommon Stock 10,000 $70.00 $700,000.00
Disclosure

SEC source: 0001209191-18-054389 · doc4.xml · nonDerivative · entry 2

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,172

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: This includes an 5,619 aggregate of shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
October 03, 2018 Filed Oct 5, 2018 20:30 UTC
Trower PaulPrincipal Accounting Officer
Exercise / conversionCommon Stock 10,000 $17.79 $177,900.00
Disclosure

SEC source: 0001209191-18-054389 · doc4.xml · nonDerivative · entry 1

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,172

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 03, 2018 Filed Oct 5, 2018 20:29 UTC
SWAIN PAULA JEVP, Human Resources
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 10,000 $0.00 Strike: $18.32 $0.00
Disclosure

SEC source: 0001209191-18-054387 · doc4.xml · derivative · entry 3

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,782

Underlying: Common Stock · 10,000 shares

Expires 2020-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

Read SEC document
October 03, 2018 Filed Oct 5, 2018 20:29 UTC
SWAIN PAULA JEVP, Human Resources
SaleCommon Stock 10,000 $70.00 $700,000.00
Disclosure

SEC source: 0001209191-18-054387 · doc4.xml · nonDerivative · entry 2

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,324

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
October 03, 2018 Filed Oct 5, 2018 20:29 UTC
SWAIN PAULA JEVP, Human Resources
Exercise / conversionCommon Stock 10,000 $18.32 $183,200.00
Disclosure

SEC source: 0001209191-18-054387 · doc4.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,324

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 03, 2018 Filed Oct 5, 2018 20:23 UTC
Flannelly Barry PEVP & General Manager US
SaleCommon Stock 1,000 $70.00 $70,000.00
Disclosure

SEC source: 0001209191-18-054382 · doc4.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,427

F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:06 UTC
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
GrantCommon Stock 275 $69.08 $18,997.00
Disclosure

SEC source: 0001638599-18-001150 · doc4_5715.xml · nonDerivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 810,564

F4 · ownership.nature: 275 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F8 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 810,564 shares of common stock of the Issuer beneficially owned by 14159, a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159. Includes beneficial ownership of 2,858 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 115,000 shares received previously from exercise of 115,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F11 · ownership.nature: The 275 shares are reported for each of the Funds as each has an indirect pecuniary interest.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:06 UTC
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
GrantCommon Stock 275 $69.08 $18,997.00
Disclosure

SEC source: 0001638599-18-001150 · doc4_5715.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 29,268,495

F4 · ownership.nature: 275 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F7 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 29,268,495 shares of common stock of the Issuer beneficially owned by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Includes beneficial ownership of 2,858 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 115,000 shares received previously from exercise of 115,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F11 · ownership.nature: The 275 shares are reported for each of the Funds as each has an indirect pecuniary interest.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:06 UTC
BAKER BROS. ADVISORS LPDirector · 10% owner
14159, L.P.Director · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
GrantCommon Stock 275 $69.08 $18,997.00
Disclosure

SEC source: 0001638599-18-001150 · doc4_5715.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

14159, L.P. · CIK 0001551138 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,407,966

F4 · ownership.nature: 275 shares of common stock (the "Common Stock") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of director retainer fees of $19,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's Board of Directors (the "Board") as a representative of the Funds (as defined below).

F5 · ownership.nature: Pursuant to the policies of Baker Bros. Advisors LP (the "Adviser"), Julian C. Baker does not have any right to the pecuniary interest in the Issuer's securities issued in lieu of director retainer fees and the Funds (as defined below) are entitled to an indirect proportionate pecuniary interest in the securities. 667, L.P. ("667"), Baker Brothers Life Sciences, L.P. ("Life Sciences") and 14159, L.P. ("14159", and together with 667, and Life Sciences, the "Funds") each owns an indirect proportionate pecuniary interest in the shares of Common Stock. Solely as a result of their ownership interest in the general partners of the general partners of the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock issued in lieu of director retainer fees (ie. no direct pecuniary interest).

F6 · ownership.nature: As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 4,407,966 shares of common stock of the Issuer beneficially owned by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. Includes beneficial ownership of 2,858 shares issued pursuant to the Stock Incentive Plan in lieu of director retainer fees and 115,000 shares received previously from exercise of 115,000 stock options of the Issuer that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the fund may be deemed to own a portion.

F9 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are Managing Members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F10 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F11 · ownership.nature: The 275 shares are reported for each of the Funds as each has an indirect pecuniary interest.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 20:19 UTC GrantCommon Stock 180 $69.08 $12,434.40
Disclosure

SEC source: 0001209191-18-053114 · doc4.xml · nonDerivative · entry 1

FOUSE JACQUALYN A · CIK 0001405288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 516

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 20:27 UTC GrantCommon Stock 343 $69.08 $23,694.44
Disclosure

SEC source: 0001209191-18-053138 · doc4.xml · nonDerivative · entry 1

BROOKE PAUL A · CIK 0001175940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 198,556

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 20:11 UTC GrantCommon Stock 209 $69.08 $14,437.72
Disclosure

SEC source: 0001209191-18-053090 · doc4.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,668

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 20:15 UTC GrantCommon Stock 235 $69.08 $16,233.80
Disclosure

SEC source: 0001209191-18-053099 · doc4.xml · nonDerivative · entry 1

DIXON WENDY L · CIK 0001202283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,944

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

Read SEC document
September 04, 2018 Filed Sep 6, 2018 20:30 UTC
SWAIN PAULA JEVP, Human Resources
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 10,000 $0.00 Strike: $18.32 $0.00
Disclosure

SEC source: 0001209191-18-049827 · doc4.xml · derivative · entry 3

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,782

Underlying: Common Stock · 10,000 shares

Expires 2020-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

Read SEC document
September 04, 2018 Filed Sep 6, 2018 20:30 UTC
SWAIN PAULA JEVP, Human Resources
SaleCommon Stock 10,000 $73.21 $732,100.00
Disclosure

SEC source: 0001209191-18-049827 · doc4.xml · nonDerivative · entry 2

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,324

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents weighted average sale price. Actual sale prices ranged from $72.84 - $73.89.

F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.

F4 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
September 04, 2018 Filed Sep 6, 2018 20:30 UTC
SWAIN PAULA JEVP, Human Resources
Exercise / conversionCommon Stock 10,000 $18.32 $183,200.00
Disclosure

SEC source: 0001209191-18-049827 · doc4.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,324

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 21, 2018 Filed Aug 22, 2018 20:02 UTC
SWAIN PAULA JEVP, Human Resources
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 10,000 $0.00 Strike: $18.32 $0.00
Disclosure

SEC source: 0001209191-18-047908 · doc4.xml · derivative · entry 3

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,782

Underlying: Common Stock · 10,000 shares

Expires 2020-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.

Read SEC document
August 21, 2018 Filed Aug 22, 2018 20:02 UTC
SWAIN PAULA JEVP, Human Resources
SaleCommon Stock 10,000 $70.00 $700,000.00
Disclosure

SEC source: 0001209191-18-047908 · doc4.xml · nonDerivative · entry 2

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,324

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
August 21, 2018 Filed Aug 22, 2018 20:02 UTC
SWAIN PAULA JEVP, Human Resources
Exercise / conversionCommon Stock 10,000 $18.32 $183,200.00
Disclosure

SEC source: 0001209191-18-047908 · doc4.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,324

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 16, 2018 Filed Jul 18, 2018 21:22 UTC
Wenqing YaoEVP, Head of Discovery Chem
Tax withholdingCommon Stock 430 $70.19 $30,181.70
Disclosure

SEC source: 0001209191-18-043120 · doc4.xml · nonDerivative · entry 1

Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,217

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2018 Filed Jul 18, 2018 21:16 UTC
Trower PaulPrincipal Accounting Officer
Tax withholdingCommon Stock 196 $70.19 $13,757.24
Disclosure

SEC source: 0001209191-18-043115 · doc4.xml · nonDerivative · entry 1

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,172

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 2,925 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2018 Filed Jul 18, 2018 21:12 UTC
SWAIN PAULA JEVP, Human Resources
Tax withholdingCommon Stock 639 $70.19 $44,851.41
Disclosure

SEC source: 0001209191-18-043111 · doc4.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,324

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2018 Filed Jul 18, 2018 21:06 UTC
Stein Steven HEVP & Chief Medical Officer
Tax withholdingCommon Stock 577 $70.19 $40,499.63
Disclosure

SEC source: 0001209191-18-043106 · doc4.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,620

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2018 Filed Jul 18, 2018 20:28 UTC
Huber Reid MEVP, Chief Scientific Officer
Tax withholdingCommon Stock 448 $70.19 $31,445.12
Disclosure

SEC source: 0001209191-18-043040 · doc4.xml · nonDerivative · entry 1

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,571

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2018 Filed Jul 18, 2018 20:25 UTC
Hoppenot HerveDirector · Chairman / CEO · President
Tax withholdingCommon Stock 2,359 $70.19 $165,578.21
Disclosure

SEC source: 0001209191-18-043035 · doc4.xml · nonDerivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,766

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 164,837 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2018 Filed Jul 18, 2018 20:09 UTC
Flannelly Barry PEVP & General Manager US
Tax withholdingCommon Stock 430 $70.19 $30,181.70
Disclosure

SEC source: 0001209191-18-043025 · doc4.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,427

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 16, 2018 Filed Jul 18, 2018 20:12 UTC
GRYSKA DAVID WExecutive Vice President, CFO
Tax withholdingCommon Stock 455 $70.19 $31,936.45
Disclosure

SEC source: 0001209191-18-043028 · doc4.xml · nonDerivative · entry 1

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,235

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 8,026 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 09, 2018 Filed Jul 11, 2018 20:41 UTC
SWAIN PAULA JEVP, Human Resources
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative 10,000 $0.00 Strike: $18.32 $0.00
Disclosure

SEC source: 0001209191-18-042343 · doc4.xml · derivative · entry 3

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,782

Underlying: Common Stock · 10,000 shares

Expires 2020-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years

Read SEC document
July 09, 2018 Filed Jul 11, 2018 20:41 UTC
SWAIN PAULA JEVP, Human Resources
SaleCommon Stock 10,000 $71.11 $711,100.00
Disclosure

SEC source: 0001209191-18-042343 · doc4.xml · nonDerivative · entry 2

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,963

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: Represents weighted average sale price. Actual sale prices ranged from $70.27 - $71.68.

F3 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated.

F4 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 09, 2018 Filed Jul 11, 2018 20:41 UTC
SWAIN PAULA JEVP, Human Resources
Exercise / conversionCommon Stock 10,000 $18.32 $183,200.00
Disclosure

SEC source: 0001209191-18-042343 · doc4.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 09, 2018 Filed Jul 11, 2018 20:39 UTC
Iyengar Vijay KEVP GPS, BD, & Licensing
SaleCommon Stock 606 $71.34 $43,232.04
Disclosure

SEC source: 0001209191-18-042339 · doc4.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,103

F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.

F2 · balance_after: Includes an aggregate of 7,270 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 05, 2018 Filed Jul 5, 2018 21:12 UTC
GRYSKA DAVID WExecutive Vice President, CFO
Tax withholdingCommon Stock 280 $68.28 $19,118.40
Disclosure

SEC source: 0001209191-18-041743 · doc4.xml · nonDerivative · entry 1

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,690

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 05, 2018 Filed Jul 5, 2018 21:04 UTC
Huber Reid MEVP, Chief Scientific Officer
Tax withholdingCommon Stock 284 $68.28 $19,391.52
Disclosure

SEC source: 0001209191-18-041730 · doc4.xml · nonDerivative · entry 1

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,019

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 05, 2018 Filed Jul 5, 2018 21:18 UTC
Hoppenot HerveDirector · Chairman / CEO · President
Tax withholdingCommon Stock 1,532 $68.28 $104,604.96
Disclosure

SEC source: 0001209191-18-041748 · doc4.xml · nonDerivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,125

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 170,238 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 05, 2018 Filed Jul 5, 2018 20:58 UTC
Iyengar Vijay KEVP GPS, BD, & Licensing
Tax withholdingCommon Stock 273 $68.28 $18,640.44
Disclosure

SEC source: 0001209191-18-041719 · doc4.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,709

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 7,270 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 05, 2018 Filed Jul 5, 2018 20:49 UTC
Flannelly Barry PEVP & General Manager US
Tax withholdingCommon Stock 273 $68.28 $18,640.44
Disclosure

SEC source: 0001209191-18-041702 · doc4.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,857

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 05, 2018 Filed Jul 5, 2018 20:45 UTC
Stein Steven HEVP & Chief Medical Officer
Tax withholdingCommon Stock 262 $68.28 $17,889.36
Disclosure

SEC source: 0001209191-18-041685 · doc4.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,197

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 05, 2018 Filed Jul 5, 2018 20:28 UTC
SWAIN PAULA JEVP, Human Resources
Tax withholdingCommon Stock 404 $68.28 $27,585.12
Disclosure

SEC source: 0001209191-18-041628 · doc4.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,963

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 05, 2018 Filed Jul 5, 2018 20:22 UTC
Wenqing YaoEVP, Head of Discovery Chem
Tax withholdingCommon Stock 273 $68.28 $18,640.44
Disclosure

SEC source: 0001209191-18-041610 · doc4.xml · nonDerivative · entry 1

Wenqing Yao · CIK 0001624033 · EVP, Head of Discovery Chem

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,647

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: Includes an aggregate of 9,415 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

Read SEC document
July 05, 2018 Filed Jul 5, 2018 20:24 UTC
Trower PaulPrincipal Accounting Officer
Tax withholdingCommon Stock 101 $68.28 $6,896.28
Disclosure

SEC source: 0001209191-18-041613 · doc4.xml · nonDerivative · entry 2

Trower Paul · CIK 0001642041 · Principal Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,368

F3 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

Read SEC document
July 02, 2018 Filed Jul 5, 2018 21:12 UTC
GRYSKA DAVID WExecutive Vice President, CFO
GrantEmployee Stock Option (right to buy) · Derivative 22,772 $0.00 Strike: $68.62 $0.00
Disclosure

SEC source: 0001209191-18-041743 · doc4.xml · derivative · entry 2

GRYSKA DAVID W · CIK 0001202335 · Executive Vice President, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,772

Underlying: Common Stock · 22,772 shares

Expires 2028-07-01

F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Read SEC document
July 02, 2018 Filed Jul 5, 2018 21:04 UTC
Huber Reid MEVP, Chief Scientific Officer
GrantEmployee Stock Option (right to buy) · Derivative 22,772 $0.00 Strike: $68.62 $0.00
Disclosure

SEC source: 0001209191-18-041730 · doc4.xml · derivative · entry 2

Huber Reid M · CIK 0001607052 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,772

Underlying: Common Stock · 22,772 shares

Expires 2028-07-01

F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Read SEC document
July 02, 2018 Filed Jul 5, 2018 21:18 UTC
Hoppenot HerveDirector · Chairman / CEO · President
GrantEmployee Stock Option (right to buy) · Derivative 88,557 $0.00 Strike: $68.62 $0.00
Disclosure

SEC source: 0001209191-18-041748 · doc4.xml · derivative · entry 3

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,557

Underlying: Common Stock · 88,557 shares

Expires 2028-07-01

F4 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Read SEC document
July 02, 2018 Filed Jul 5, 2018 20:58 UTC
Iyengar Vijay KEVP GPS, BD, & Licensing
GrantEmployee Stock Option (right to buy) · Derivative 22,772 $0.00 Strike: $68.62 $0.00
Disclosure

SEC source: 0001209191-18-041719 · doc4.xml · derivative · entry 2

Iyengar Vijay K · CIK 0001670000 · EVP GPS, BD, & Licensing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,772

Underlying: Common Stock · 22,772 shares

Expires 2018-07-01

F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Read SEC document
July 02, 2018 Filed Jul 5, 2018 20:53 UTC
Pasquale Maria EEVP & General Counsel
GrantEmployee Stock Option (right to buy) · Derivative 22,772 $0.00 Strike: $68.62 $0.00
Disclosure

SEC source: 0001209191-18-041712 · doc4.xml · derivative · entry 1

Pasquale Maria E · CIK 0001736295 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,772

Underlying: Common Stock · 22,772 shares

Expires 2028-07-01

F1 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Read SEC document
July 02, 2018 Filed Jul 5, 2018 20:49 UTC
Flannelly Barry PEVP & General Manager US
GrantEmployee Stock Option (right to buy) · Derivative 22,772 $0.00 Strike: $68.62 $0.00
Disclosure

SEC source: 0001209191-18-041702 · doc4.xml · derivative · entry 2

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,772

Underlying: Common Stock · 22,772 shares

Expires 2028-07-01

F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Read SEC document
July 02, 2018 Filed Jul 5, 2018 20:45 UTC
Stein Steven HEVP & Chief Medical Officer
GrantEmployee Stock Option (right to buy) · Derivative 22,772 $0.00 Strike: $68.62 $0.00
Disclosure

SEC source: 0001209191-18-041685 · doc4.xml · derivative · entry 2

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,772

Underlying: Common Stock · 22,772 shares

Expires 2028-07-01

F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.